Clinical Trials Browser

Colonic Neoplasms

NCT05731726 2026-03-05

Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer

Phase 2 Recruiting

50 enrolled

Gastrointestinal

Rectal Neoplasms

NCT02574728 2026-03-02

AflacST1502

Phase 2 Active not recruiting

46 enrolled

CNSMyeloidSarcoma

Brain Neoplasms, Carcinoma, Ependymoma, Histiocytosis, Langerhans-Cell, Medulloblastoma, Neoplasms, Neoplasms, Germ Cell and Embryonal, Neuroblastoma, Pinealoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Rhabdoid Tumor

Clinical Trials

NICHE

Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer

AflacST1502

Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma

MEMMAT

Window of Opportunity Study Targeting the Inflammatory Milieu

The Seven Trial: Exploiting the Unfolded Protein Response

PICC

Phase II RCT of LCRT vs SCRT + CAPOX/PD-1i/COX-2i in MSS Locally Advanced Rectal Cancer

Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC)

Triple Negative Breast Cancer and Celecoxib. Pilot Study

BLAST

Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Oral Cavity Cancer in a Rural Midwest United States Population

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer

Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines

Celecoxib for Prevention of Progression in Peutz-Jeghers Syndrome

PICC-3